Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onradivir DDI Study with Digoxin, Rosuvastatin, Itraconazole, and Probenecid
NCT05954624Phase 1Completed
- Sponsor
- Raynovent Biotech
- Start
- Jul 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of anlatrelvir in Influenza A (IAV) (2 arms), sponsored by Raynovent Biotech. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve. Started Jul 2023; status: completed.
02
Drugs
anlatrelvir
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT05954624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05954624.